At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
Furosemidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Pilot Study
In Brief
A Phase 1 clinical trial evaluating Furosemide for Acute Heart Failure. Completed, enrolled 40 participants across 5 sites.
Detailed Summary
The Pilot study is designed to evaluate the overall safety and feasibility of a strategy based on subcutaneous delivery of furosemide. It will be used to inform the subsequent evaluation phase of the study (separate protocol). The primary objective of the study is to determine if a strategy of a novel subcutaneous delivery of furosemide is safe and feasible in patients with acute heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Heart Failure
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartDec 2016
Primary CompletionNov 2017
TodayJul 2026
First PostedAug 24, 2016
Enrollment StartDec 19, 2016
Primary CompletionNov 7, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.9 years ago
Interventions
Furosemidedrug
subcutaneous furosemide delivered via subcutaneous pump